N&N Pharmaceuticals (N&N) is a privately held biopharmaceutical company located in the biotech hub of Montgomery County (MD, USAO. The company has announced the beginning of Phase I clinical trials of their novel antiviral drug, N-Methanocarbathymidine (known as N-MCT).
These trials will define the safety and pharmacokinetic of the drug. The trials are currently taking place at Georgetown University Hospital, Division of Infectious Diseases. Dr Princy Kumar will serve as Principal Clinician during this period.
Dr Aquilur Rahman, President and CEO of N&N, commented: “We are highly pleased to begin these clinical trials of this novel antiviral drug. We have seen a high spectrum of activity of this drug in multiple viral diseases. N-MCT has shown significant activity in shingles, genital herpes, neonatal herpes and in smallpox.”
He added that the company will “pursue shingles as the first indication for N-MCT. In preclinical studies with shingle models, N-MCT has shown significantly more pronounced antiviral activity than any other known commercially available drug on the market.”
He continued to note that “the Asian subsidiary of N&N, located in Korea, will soon start clinical trials of this wide spectrum antiviral agent N-MCT. We hope to expedite the clinical trials in Korea in the upcoming months; the data will supplement the clinical data being gathered and generated in the US.”
“There is a significant number of shingle cases in Korea, amounting to about 460,000 per year. In the US, about one million cases of shingles are reported annually. Thus, we hope to prioritize the clinical evaluation of N-MCT’s activity on this particular disease, and look forward to a swift drug development and commercialization with the coordination of US and Asian clinical trials.”